%0 Systematic Review
%T Risk of erythrocytosis in transgender individuals undergoing testosterone therapy: a systematic review.
%A Scala A
%A Graziani A
%A Vianello F
%A Ferlin A
%A Garolla A
%A  
%J Minerva Endocrinol (Torino)
%V 49
%N 2
%D 2024 Jun
%M 39028210
%F 3.757
%R 10.23736/S2724-6507.24.04171-X
%X <B>BACKGROUND: </B>In transgender individuals assigned female at birth, testosterone therapy is employed for body masculinization. Guidelines recommend close monitoring for potential side effects of hormonal therapy, especially during the first year. Erythrocytosis is a common finding during testosterone therapy and has been associated with a potential risk of thrombotic and cardiovascular events. Currently, the hematologic effects of testosterone therapy are understudied, with existing data primarily derived from the cisgender male population. The aim of this study was to comprehensively examine the hematological changes induced by testosterone therapy in the transgender population.<BR><B>METHODS: </B>A systematic search was conducted using the electronic database PubMed.<BR><B>RESULTS: </B>Thirty-six manuscripts were retrieved. After screening for original studies, 19 articles were included. Selected articles were published between 2005 and 2023.<BR><B>CONCLUSIONS: </B>In our systematic review, the prevalence of erythrocytosis varied from 0% to 29.3%, with severe erythrocytosis ranging from 0.5% to 2.3%. Testosterone therapy was associated with an increase in hemoglobin and hematocrit, particularly within the first year of therapy. Factors such as serum testosterone levels, along with the duration, doses, and formulation of testosterone therapy, were found to be associated with the development of erythrocytosis. Further research is crucial to provide specific recommendations for clinical practice.